Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.

AIDS (London, England) - 1 Nov 2015

Oliveira Maureen, Mesplède Thibault, Moïsi Daniela, Ibanescu Ruxandra-Ilinca, Brenner Bluma, Wainberg Mark A

Abstract excerpt

OBJECTIVE: Although the integrase inhibitor dolutegravir (DTG) has demonstrated greater resilience than other antiretroviral drugs at withstanding the emergence of HIV-1 resistance mutations, such substitutions can develop, albeit rarely, in treatment-experienced integrase inhibitor-naïve individuals. The most common substitution in integrase under those circumstances is R263K whereas another substitution that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heterocyclic Compounds, 3-Ring
Share to HIV Integrase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Oxazines

Share to Piperazines

Share to Pyridones

Share to Quinolones

Share to Raltegravir Potassium

Share to Virus Cultivation

Source

Identifiers

PMID: 26372484
DOI: 10.1097/QAD.0000000000000866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.PMID 26372484Read ↗

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitorsSemantic proximity Read ↗

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravirSemantic proximity Read ↗

Dolutegravir Resistance Mutation R263K Cannot Coexist in Combination with Many Classical Integrase Inhibitor Resistance SubstitutionsSemantic proximity Read ↗

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.Semantic proximity Read ↗

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.Semantic proximity Read ↗

A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.Semantic proximity Read ↗

The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer InhibitorsSemantic proximity Read ↗

Emerging patterns and implications of HIV-1 integrase inhibitor resistanceSemantic proximity Read ↗

Dolutegravir resistance mutations: lessons from monotherapy studies.Semantic proximity Read ↗

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressureSemantic proximity Read ↗

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.Semantic proximity Read ↗

Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor DolutegravirSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.